We act as a common voice for hepatitis patients on the local, state and federal level.
We passionately take policy positions which favor patients and their access to care.
We use grassroots support to drive legislation that puts patients' care first.
We are community based advocates and stakeholders. Our drive for research and
policy improvements are for viral hepatitis treatment, prevention and vaccines.
Although 2017 was a watershed moment in U.S. politics, the considerable momentum
generated by robust activism and advocacy catapulted
The California Hepatitis C Task Force into a formidable position
for advancing important policy priorities over the next four years.
Some of the important issues the Task Force will focus on in the coming years are:
Addressing domestic drug pricing concerns for viral hepatitis medications
Capitalizing on greater statewide political attention to infectious disease
Advancing the vision for healthcare access that is universally
available as a right for all citizens, in keeping with the transformation that is occurring globally
Issues, Policies & Positions
YEAR
BILL
AUTHOR
TITLE
(POSITION)
2015
AB 374
Navarian
Step Therapy Override Determination
(Letter of Support)
2015
AB 383
Gipson
Hepatitis Education Screening & Treatment Act
(Letter of Support)
2015
AB 623
-
Wood
Preventing Prescription Drug Abuse
(Letter of Support)
2015
AB 187
-
Bonta
Medi-Cal Managed Care California Services Program
(Letter of Support)
2015
SB 675
-
Liu
Transitional Care
(Letter of Support)
2016
AB 463
-
Chiu
Drug Price Controls
(Letter of Concern)
2016
CAHCVTF
Sign-on Letter to Members of United States Congress; 340B Federal Drug Discount Program
(Letter of Concern)
2016
CAHCVTF
Letter to Attorney General Kamala Harris Regarding Merger of Insurance Plans
(Letter of Concern)
2016
CAHCVTF
Letter to Governor Edmund G. Brown Jr.; Request for Proclamation in support of May 19 National Hepatitis Testing Day in California
(Letter of Request)
2016
CAHCVTF
Letter to Budget Subcommittee Chair, CCS Trailer Bill Language per DHCS Item for 4260 (#607)
(Letter of Opposition)
2016
AB 2084
Wood
Comprehensive Medication Management Benefit in the Medi-Cal Program (CMM)
(Letter of Support)
2016
AB 2531
Burke
Pay Equity Bill for Reproductive Research
(Letter of Support)
2016
AB 2752
Navarian
Continuity of Care
(Letter of Support)
2016
CAHCVTF
Letter to the Chair of Health & Children's Services regarding Title 5 Application for Block Grant funding at CCS
(Letter of Concern)
2017
AB 265
Wood
Prescription Drugs; Prohibition on Price Discount
(Letter of Opposition)
2017
SB 17
Hernandez
Heathcare: Prescription Drug Cost
(Letter of Opposition)
2017
SB 349
Lara
Chronic Dialysis Clinics; Staffing Requirements
(Letter of Opposition)
2017
AB 1353
Waldron
Essential Health Benefits; Continuity of Care
(Letter of Support)
2017
CAHCVTF
Letter to Governor Edmund G. Brown Jr., regarding Prescription Drugs; called Prescription Drugs; Prohibition on Price Discount
(Veto Request)
2017
I AM ESSENTIAL Coalition
I AM ESSENTIAL Coalition Letter to Health & Human Services Secretary Tom Price; Sign-on letter referencing maintaining and enforcing important patient protections and access to prescription drugs.
(Letter of Appeal)
2018
AB 2863
Navarian
Healthcare Coverage; Prescriptions
(Letter of Support)
2018
AB 315
Wood
Pharmacy Benefit Management
(Letter of Support)
2018
AB 845
Wood
Canabinoid Support
(Letter of Support)
2018
AB 18660
Lymon
Healthcare Coverage; Prescriptions
(Letter of Support)
2018
AB 2760
Wood
Prescriptions Drugs; Prescribers; Naloxone, Hydrochloride and other FDA approved drugs
(Letter of Support)
2018
AB 2863
Navarian
Healthcare Coverage; Prescriptions
(Letter of Support)
2018
AB 2893
Waldron
California Health Benefit Review Program; Financial Impacts
California Hepatitis History: In 2008, then California Governor Schwartzenegger proclaimed a Hepatitis Awareness Date,
as a Hepatitis A Emergency was proclaimed. Click on the document images to open the PDFs of these documents:
We are proud members of the global movement to eliminate viral hepatitis by 2030. Join us.